Nakata and colleagues proposed that targeting the Akt/β-catenin pathway can enhance the therapeutic efficacy of EGFR tyrosine kinase inhibitors in drug-resistant cancers, suggesting the crucial role of β-catenin in cancer progression [61]. The gene discussed is AKT1; the disease is cancer.